References
- Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004; 20: 3179–83
- Beck S., Olek A, editors. The epigenome. Molecular hide‐and‐seek. Wiley‐VCH, Weinheim 2003
- Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695–714
- Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A., Klein P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734–41
- Gottlicher M., Minucci S., Zhu P., Kramer O. H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–78
- Detich N., Bovenzi V., Szyf M. Valproate induces replication‐independent active DNA demethylation. J Biol Chem 2003; 278: 27586–92
- Tremolizzo L., Carboni G., Ruzicka W. B., Mitchell C. P., Sugaya I., Tueting P., et al. An epigenetic mouse model for molecular and behavioural neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci. USA 2002; 99: 17095–100
- Sumner C. J., Huynh T. N., Markowitz J. A., Perhac J. S., Hill B., Coovert D. D., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54: 647–54
- Kunst C. B., Messer L., Gordon J., Haines J., Patterson D. Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics 2000; 70: 181–9
- Veldink J. H., van den Berg L. H., Cobben J. M., Stulp R. P., De Jong J. M., Vogels O. J., et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 2001; 56: 753–7
- Al‐Chalabi A., Andersen P. M., Chioza B., Shaw C., Sham P. C., Robberecht W., et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 1998; 7: 2045–50
- Andersen P. M., Nilsson P., Keranen M. L., Forsgren L., Hagglund J., Karlsborg M., et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn‐superoxide dismutase mutations in Scandinavia. Brain 1997; 120: 1723–37
- Rothstein J. D., Van Kammen M., Levey A. I., Martin L. J., Kuncl R. W. Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73–84
- Su Z. Z., Leszczyniecka M., Kang D. C., Sarkar D., Chao W., Volsky D. J., et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci. USA 2003; 100: 1955–60
- Hassel B., Iversen E. G., Gjerstad L., Tauboll E. Up‐regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001; 77: 1285–92
- Morland C., Boldingh K. A., Iversen E. G., Hassel B. Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high‐affinity glutamate uptake. J Cereb Blood Flow Metab 2004; 24: 1226–34
- Bertamini M., Marzani B., Guarneri R., Guarneri P., Bigini P., Mennini T., et al. Mitochondrial oxidative metabolism in motor neuron degeneration mouse central nervous system. Eur J Neurosci 2002; 16: 2291–6
- Bigini P., Larini S., Pasquali C., Muzio V., Mennini T. Acetyl‐L‐carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motor neurons. Neurosci Lett 2002; 329: 334–8
- Pisano C., Pratesi G., Laccabue D., Zunino F., Lo Giudice P., Bellucci A., et al. Paclitaxel and cisplatin‐induced neurotoxicity: a protective role of acetyl‐L‐carnitine. Clin Cancer Res 2003; 9: 5756–67
- Tang Y., Glauscr T. A., Gilbert D. L., Hershey A. D., Privitera M. D., , Ficker D. M, et al. Valproic acid blood genomic expression patterns in children with epilepsy: a pilot study. Acta Neurol Scand 2004; 109: 159–68
- Hockly E., Richon V. M., Woodman B., Smith D. L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci. USA 2003; 100: 2041–6